NeuroPace Inc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $100.0M | $79.9M | $65.4M | $45.5M | $45.2M |
| Cost of revenue | $22.8M | $20.8M | $17.3M | $13.0M | $11.7M |
| Gross profit | $77.2M | $59.1M | $48.1M | $32.5M | $33.4M |
| Selling, general & administrative | — | $57.1M | $54.5M | $51.3M | $39.0M |
| Research and development | $27.9M | $23.7M | $20.8M | $21.9M | $18.2M |
| Operating expenses | $93.6M | $80.8M | $75.3M | $73.3M | $57.2M |
| Operating income | -$16.3M | -$21.7M | -$27.2M | -$40.8M | -$23.7M |
| Interest expense | $7.5M | $8.8M | $8.5M | $7.5M | $7.4M |
| Income tax expense | $0 | — | — | — | — |
| Net income | -$21.5M | -$27.1M | -$33.0M | -$47.1M | -$36.1M |
| Balance Sheet | |||||
| Cash and equivalents | $21.7M | $13.4M | $18.1M | $6.6M | $19.2M |
| Current assets | $94.1M | $81.3M | $92.7M | $97.7M | $132.8M |
| Total assets | $105.6M | $94.6M | $107.7M | $114.1M | $133.6M |
| Current liabilities | $17.8M | $15.2M | $16.2M | $11.0M | $9.3M |
| Total liabilities | $86.5M | $86.6M | $87.0M | $79.3M | $60.1M |
| Stockholders' equity | $19.0M | $8.0M | $20.7M | $34.8M | $73.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$11.0M | -$17.9M | -$19.7M | -$36.9M | -$24.6M |
| Depreciation and amortization | $238,000 | $207,000 | $172,000 | $267,000 | $296,000 |
| Stock-based compensation | $11.1M | $10.3M | $9.6M | $8.3M | $4.3M |
| Capital expenditure | $332,000 | $306,000 | $173,000 | $603,000 | $384,000 |
| Free cash flow | -$11.3M | -$18.3M | -$19.9M | -$37.5M | -$25.0M |
| Share repurchases | $49.5M | $0 | — | $0 | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 34.1M · Free float 57.8%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.